Veradermics (MANE) Preferred Stock Liabilities (2025)
Veradermics posted quarterly Preferred Stock Liabilities of $36.9 million for Q4 2025, down 50.66% on a QoQ basis from $74.7 million in Q1 2025.
Veradermics (MANE) has 1 years of Preferred Stock Liabilities data on file, last reported at $36.9 million in Q4 2025.
- For the quarter ending Q4 2025, Preferred Stock Liabilities changed N/A year-over-year to $36.9 million; the trailing twelve-month figure through Dec 2025 stood at $36.9 million (changed N/A YoY), and the FY2025 full-year result was $36.9 million, changed N/A from the prior year.
- Preferred Stock Liabilities for Q4 2025 stood at $36.9 million, down from $74.7 million in the prior quarter.
- Across five years, Preferred Stock Liabilities topped out at $74.7 million in Q1 2025 and bottomed at $36.9 million in Q4 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Stock Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | - |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | - |
| 10 | Veradermics | 2.29 Bn | 2.29 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 36.86 Mn |
| Mar 31, 2025 | 74.71 Mn |